http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2329555-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8925b769d645f9ff06af9f4b189f6a99 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7028 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4453 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-62 |
| filingDate | 2002-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb2c7ee773ba75ba32ab5a03ba07b6ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_778e3f534499f83221fb1dd42137b13c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d8527e752416ebbc946912a06e3a08 |
| publicationDate | 2009-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2329555-T3 |
| titleOfInvention | ANTI-DIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKES A DAY" THAT INCLUDES A BIGUADINE AND AT LEAST ANOTHER ACTIVE PRICE. |
| abstract | Associated oral pharmaceutical form: an active substance A consisting of a biguanide, namely metformin, and at least one other active substance B different from A and selected from among the antidiabetics, preferably antihyperglycemic agents, whose administration regime is one or several shots per day, characterized in that it comprises: * a plurality of capsules each consisting of a core based on metformin and a coating film applied on the core and allowing prolonged in vivo release of metformin; and possibly in the case where the administration regime of the active ingredient B is equal to several intakes per day, a plurality of capsules each consisting of a core based on active ingredient B and a coating film applied on the core and which allows prolonged release in vivo of active ingredient B; because the capsules based on A and the eventual capsules based on B are designed in such a way that the administration regime of the galenic form considered is one dose per day; because the capsules have a granulometry between 50 and 1,000 ml, preferably between 100 and 750 ml, and more preferably still, between 200 and 500 ml; and because the composition of the coating film of the capsules is as follows: 1) - at least one film-forming polymer (P1) insoluble in the liquids of the tract, present at a rate of 50 to 90, preferably 50 to 80% in dry weight in relation to the total mass of the coating composition and consisting of at least one non-water soluble cellulose derivative, namely ethyl cellulose and / or cellulose acetate; 2) - at least one nitrogen polymer (P2) present at a rate of 2 to 25, preferably 5 to 15% by dry weight in relation to the total mass of the coating composition and consisting of at least one polyacrylamide and / or a poly-N-vinyl amide and / or a poly-N-vinyl-lactam, namely polyacrylamide and / or polyvinylpyrrolidone; 3) - at least one plasticizer present at a rate of 2 to 20, preferably 4 to 15% by dry weight in relation to the total mass of the coating composition and consisting of at least one of the following compounds: glycerol esters, phthalates, citrates, sebacates, cetyl alcohol esters, castor oil; and 4) - optionally at least one surfactant and / or lubricant, present at a rate of 2 to 20, preferably 4 to 15% by dry weight in relation to the total mass of the coating composition and selected from among the anionic surfactants, namely alkaline or alkaline earth salts of fatty acids, with stearic and / or oleic acid being preferred, and / or among non-ionic surfactants, namely polyoxyethylene sorbitan esters and / or derivatives of polyoxyethylene castor oil, and / or among lubricating agents such as calcium, magnesium, aluminum or zinc stearates, or as sodium stearyl fumarate and / or glycerol behenate; said agent may comprise only one or a mixture of said products. |
| priorityDate | 2001-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 197.